Growth of one of these variants (L1210/R69), with metoprine in the presence of decreasing concentrations of l,L5-CHO-folateH 4 (natural diastereoisomer of 5-formyltetrahydrofolate), resulted in the selection of other variants (L1210/R82, R83, and R84) with further reduction in one-carbon, reduced folate transport and in two cases (L1210/R83 and R84) with 3-8-fold increased folylpolyglutamate synthetase (FPGS) activity and folate compound polyglutamate formation in situ. Metoprine resistance was further increased, and the requirement for exogenous folate during growth was decreased as well in these variants. The increase in FPGS activity observed in L1210/R83 and R84 was characterized by 3-and 8-fold increases in value for V max with no change in K m and the same increase in a 60 -61-kDa protein as shown by immunoblotting. Northern blotting revealed the same increases in these two variants in the level of a 2.3-kilobase FPGS mRNA when compared with control, while Southern blotting of genomic DNA did not reveal any increase in FPGS gene-copy number or restriction polymorphisms. Also, no difference in stability of FPGS mRNA was found between parental and variant cells. In contrast, nuclear run-on assays revealed differences among these cell types in the rate of FPGS mRNA transcription that correlated with increased FPGS activity, protein, and mRNA level in the variants. Similar studies with a transport-defective, methotrexate-resistant L1210 cell variant (L1210/R25) documented a 2-3-fold decrease in FPGS activity, protein, and mRNA levels that was accounted for by a decrease in FPGS mRNA transcription. These results provide the first examples of constituitively altered transcriptional regulation of FPGS activity associated with acquired resistance to antifolates.Cellular folates exist primarily as ␥-polyglutamate peptides (1-5) of varying chain length. Their metabolism to polyglutamates and that of folate analogues are mediated (1-5) by the enzyme, folylpolyglutamate synthetase (FPGS), 1 and metabolic turnover of these anabolites appears to be modulated by folylpolyglutamate hydrolase after their mediated entry into lysosomes (for review, see Ref. 6). In tumors and normal proliferative tissues of animals and man, the process of polyglutamylation has pharmacologic relevance with respect to the cytotoxicity (8, 9) and therapeutic utility (7-13) of classical folate analogues. Also, both decreased levels of FPGS activity (14, 15) and increased levels of folylpolyglutamate hydrolase activity (16) have been associated with acquired resistance to these analogues. The mechanistic basis for these alterations remain to be elucidated.The process of folylpolyglutamylation in normal proliferative and neoplastic mammalian tissues is important (1-5) to the conservation and efficient utility of folate coenzymes that are required for one-carbon transfer reactions during macromolecular biosynthesis. Consequently, levels of FPGS activity appear to be highest in the proliferative fraction of normal differentiating tissues (7,(17)(18)(...